CJC-1295 With DAC vs. Without DAC: A Complete Research Comparison
If you've spent any time exploring growth hormone secretagogue research, you've almost certainly encountered CJC-1295 — and the inevitable question that follows: with DAC or without? The distinction isn't just marketing language. It reflects a genuine and meaningful difference in molecular pharmacokinetics (how a compound moves through and is eliminated from a biological system) that has measurable consequences for research design.
This article breaks down both variants in detail, comparing their mechanisms, published research profiles, stability characteristics, and practical considerations for researchers working with these compounds.
Introduction
CJC-1295 is a synthetic analogue of GHRH (Growth Hormone-Releasing Hormone) — a naturally occurring peptide produced in the hypothalamus (a brain region that coordinates hormonal signaling) that stimulates the pituitary gland to release growth hormone (GH). Native GHRH has a very short half-life in circulation, typically under 10 minutes, because it is rapidly degraded by an enzyme called DPP-IV (dipeptidyl peptidase IV).
CJC-1295 was developed to overcome this limitation. Researchers modified the original GHRH(1-29) sequence — the biologically active fragment — with strategic amino acid substitutions that confer resistance to enzymatic breakdown. The result is a compound with substantially extended activity compared to native GHRH.
The two variants in common research use are:
- CJC-1295 with DAC — contains a Drug Affinity Complex (DAC), a lysine-maleimidoproprionic acid linker that enables covalent binding to serum albumin (the most abundant protein in blood), dramatically extending its half-life
- CJC-1295 without DAC — also known as Modified GRF(1-29) or Mod GRF(1-29), lacks this linker and relies solely on amino acid substitutions for enzymatic resistance
The presence or absence of the DAC moiety is the single most consequential structural difference between these two variants, producing a roughly 100-fold difference in circulating half-life in published animal models.
Both compounds interact with the same receptor — the GHRH receptor (GHRHR) on pituitary somatotroph cells (the specialized cells responsible for producing and releasing GH). The downstream effect in both cases is stimulation of GH secretion. The difference lies entirely in how long and in what pattern that stimulation occurs.
Mechanism of Action
Shared Molecular Pathway
Both CJC-1295 variants bind to and activate the GHRHR, a G protein-coupled receptor (GPCR) — a class of membrane proteins that translate extracellular signals into intracellular responses. Upon binding, the receptor activates adenylyl cyclase, an enzyme that produces cyclic AMP (cAMP), a second messenger molecule. Elevated cAMP activates protein kinase A (PKA), which ultimately triggers both the synthesis and secretion of growth hormone from pituitary somatotrophs.
This pathway mirrors what endogenous GHRH does, which is part of why these compounds have been of significant research interest — they appear to work within the body's existing hormonal architecture rather than bypassing it.
How DAC Changes the Equation
The DAC (Drug Affinity Complex) is a chemical linker attached to the lysine at position 12 (or an added lysine residue, depending on formulation) of the peptide chain. This linker contains a maleimide group — a reactive chemical structure that forms a stable covalent bond with the cysteine-34 residue on serum albumin.
Serum albumin has a circulating half-life of approximately 19 days in humans and serves as a natural carrier protein for many endogenous molecules. By hitching to albumin, CJC-1295 with DAC effectively borrows this extended circulation time.
The DAC technology was developed based on the observation that many peptide drugs fail clinically not because of poor receptor affinity, but because they are cleared from circulation before they can exert sustained biological effects.
In practical terms for research:
| Property | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Also known as | CJC-1295 DAC | Mod GRF(1-29) |
| Half-life (animal models) | ~6–8 days | ~30 minutes |
| Albumin binding | Yes (covalent) | No |
| GH release pattern | Sustained, blunted pulsatility | Preserves pulsatile pattern |
| Typical research dosing interval | Once or twice weekly | Acute / per-pulse protocols |
| IGF-1 elevation (sustained) | Yes | Depends on protocol |
The Pulsatility Question
This is where the mechanistic difference becomes most interesting from a research standpoint. Natural GH secretion is pulsatile — it occurs in discrete bursts, primarily during sleep, separated by periods of near-zero GH levels. This pulsatile pattern is thought to be physiologically important for receptor sensitivity and downstream signaling.
CJC-1295 without DAC has a short enough action window that it can be used to mimic or augment individual GH pulses — a single administration produces a relatively brief elevation in GH, analogous (though not identical) to an endogenous pulse.
CJC-1295 with DAC, by contrast, produces a prolonged, continuous GHRHR stimulation. This blunts pulsatility and creates what some researchers describe as a "GH bleed" — a steady rather than episodic elevation in circulating GH and IGF-1 (Insulin-like Growth Factor 1, a downstream mediator of many GH effects produced primarily in the liver).
Neither pattern is inherently superior for all research contexts. The appropriate choice depends on what a given research protocol is designed to investigate.
Published Research
CJC-1295 with DAC: Key Studies
Teichman et al. (2006) published what remains the most frequently cited clinical pharmacology study of CJC-1295 with DAC. In this randomized, placebo-controlled study published in The Journal of Clinical Endocrinology & Metabolism (PMID: 16352683), researchers administered single and multiple doses of CJC-1295 to healthy adult subjects. The findings were notable:
A single administration of CJC-1295 with DAC produced mean GH increases of 2- to 10-fold for 6 or more days, and mean IGF-1 increases of 1.5- to 3-fold that were sustained for 9–11 days. No serious adverse events were reported, and the compound was described as "well tolerated."
This study established the pharmacokinetic profile that makes CJC-1295 with DAC distinctive — the albumin-binding mechanism translated into the extended half-life predicted by preclinical models.
Ionescu and Frohman (2006) (PMID: 16352686) provided complementary mechanistic analysis, examining how GHRH analogues with extended half-lives affect pituitary GH reserves and somatotroph function. Their work helped contextualize the sustained IGF-1 elevations seen with DAC-containing compounds, noting that prolonged GHRHR stimulation appears to progressively mobilize GH stores from the pituitary.
CJC-1295 without DAC: Key Studies
Research on Mod GRF(1-29) (CJC-1295 without DAC) in its standalone form is somewhat less extensive in the clinical literature, though the compound has been widely studied in the context of GHRH analogue pharmacology.
Alba et al. (2006) conducted relevant work examining the effects of modified GHRH peptides on GH pulse amplitude and frequency in animal models. Their research demonstrated that compounds with the amino acid substitutions present in Mod GRF(1-29) — particularly the substitution of alanine at position 2 (which confers DPP-IV resistance) — produce robust but transient GH pulses consistent with the compound's shorter half-life.
Research suggests that DPP-IV-resistant GHRH analogues without albumin-binding technology retain the pulsatile GH release kinetics that more closely resemble endogenous secretion patterns, which may be important for certain downstream receptor dynamics.
Jimenez-Reina et al. and related research groups have examined how the pattern of GHRHR stimulation — pulsatile versus sustained — affects somatostatin tone (somatostatin being the hypothalamic hormone that inhibits GH release). Sustained stimulation, as produced by CJC-1295 with DAC, appears to increase somatostatin counter-regulation over time, which may partially attenuate the GH response with repeated administration in some research models.
Comparative Pharmacokinetic Context
A useful reference point is the broader GHRH analogue literature. Frohman and Jansson (1986) (PMID: 3012356), in foundational work on GHRH(1-29) kinetics, established that even unmodified GHRH fragments have measurable activity, but their rapid clearance by DPP-IV and other proteases severely limits their research utility. The modifications incorporated into both CJC-1295 variants were directly informed by this line of investigation.
| Study | Compound | Key Finding | PMID |
|---|---|---|---|
| Teichman et al., 2006 | CJC-1295 with DAC | 6+ day GH elevation; 9–11 day IGF-1 elevation | 16352683 |
| Ionescu & Frohman, 2006 | GHRH analogues | Sustained stimulation mobilizes pituitary GH reserves | 16352686 |
| Frohman & Jansson, 1986 | GHRH(1-29) | Established baseline kinetics for analogue development | 3012356 |
Practical Research Information
Solubility and Reconstitution
Both variants are supplied as lyophilized powder (freeze-dried, a preservation method that removes water content to enhance stability). Standard reconstitution uses bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative) or sterile water for injection-grade preparations.
- CJC-1295 with DAC: Generally soluble at concentrations up to 1–2 mg/mL in bacteriostatic water. The DAC moiety does not significantly impair solubility under standard conditions.
- CJC-1295 without DAC: Similar solubility profile. Some researchers note slightly easier reconstitution due to the shorter, less complex molecular structure.
In both cases, gentle swirling rather than vigorous shaking is recommended during reconstitution to minimize peptide denaturation (unfolding of the molecular structure, which can reduce biological activity).
Storage and Stability
Proper storage is one of the most overlooked variables in peptide research. Degraded peptide produces unreliable data, not just suboptimal results.
| Condition | CJC-1295 with DAC | CJC-1295 without DAC |
|---|---|---|
| Lyophilized, unreconstituted | 24+ months at -20°C | 24+ months at -20°C |
| Lyophilized, at 4°C (refrigerator) | 12–18 months (protected from light) | 12–18 months |
| Reconstituted, at 4°C | 4–6 weeks | 2–4 weeks |
| Freeze-thaw cycles | Minimize; max 2–3 cycles | Minimize; max 2–3 cycles |
Both compounds should be protected from light and moisture. Reconstituted solutions should be kept refrigerated and used within the stability windows above. Any solution showing cloudiness, particulate matter, or unusual color change should be considered compromised and not used in research protocols.
Research Dose Considerations
Published studies have used a range of amounts in research settings. The Teichman et al. (2006) study used research doses ranging from 30 to 120 mcg/kg in human subjects. It is worth emphasizing that research dose selection should be guided by the specific research question and relevant published literature, not by extrapolation from unrelated compounds or anecdotal sources.
For CJC-1295 without DAC, research protocols examining acute GH pulse augmentation have typically employed single-administration designs with timing relative to other variables (such as co-administration with GHRP compounds — Growth Hormone-Releasing Peptides that work through a complementary receptor pathway) being a critical design consideration.
Research Considerations
Choosing the Right Variant for Your Research Question
The choice between CJC-1295 with DAC and without DAC should be driven by the research question, not convenience. Here's a practical framework:
Use CJC-1295 with DAC when:
- The research question involves sustained IGF-1 elevation over days to weeks
- Infrequent administration windows are a research design requirement
- You are investigating the effects of chronic GHRHR stimulation on downstream markers
- Consistency of exposure across a study period is paramount
Use CJC-1295 without DAC when:
- The research question involves acute GH pulse dynamics
- Pulsatile GH release patterns are an important variable
- The protocol involves co-administration with GHRPs (see below), where timing precision matters
- You are investigating receptor sensitivity or somatostatin feedback mechanisms
The GHRP Synergy Question
A substantial body of research has examined the synergistic interaction between GHRH analogues and GHRPs — a separate class of GH secretagogues that act on the ghrelin receptor (GHSR-1a) rather than GHRHR. Published data indicates that co-administration of a GHRH analogue with a GHRP can produce GH responses significantly greater than either compound alone — a phenomenon sometimes called supra-additive or synergistic stimulation.
Research by Bowers et al. and related groups established that GHRH analogues and GHRPs act through complementary, non-overlapping mechanisms, and their co-administration produces GH responses that can exceed the sum of their individual effects (PMID: 2900121).
For researchers using CJC-1295 without DAC in combination protocols (such as with Ipamorelin, a selective GHRP), the timing of administration relative to each compound's peak action window is a critical research design variable. CJC-1295 without DAC's shorter half-life makes it amenable to acute co-administration designs where both compounds are active simultaneously.
CJC-1295 with DAC, given its sustained presence, provides a continuous GHRHR stimulation background against which acute GHRP administration can be studied.
Receptor Downregulation Considerations
A recurring question in the GHRH analogue research literature concerns whether sustained receptor stimulation — as produced by CJC-1295 with DAC — leads to GHRHR downregulation (a reduction in receptor number or sensitivity in response to prolonged stimulation, a common biological adaptation).
Published data suggests this is a relevant consideration. Studies in animal models have demonstrated that chronic continuous GHRHR stimulation can attenuate GH responses over time, which may have implications for long-term research protocols. This is one reason some researchers prefer pulsatile administration strategies using CJC-1295 without DAC, even when logistical convenience might favor the DAC variant.
Purity and Peptide Quality
For any research involving biological activity measurements, peptide purity is a critical variable. Research-grade peptides should ideally be accompanied by HPLC (High-Performance Liquid Chromatography, an analytical method that separates and quantifies components in a mixture) and mass spectrometry certificates of analysis confirming identity and purity ≥ 98%. Impurities in research peptides can confound experimental results and introduce variables that undermine data reproducibility.
Regulatory and Ethical Context
CJC-1295 variants are research compounds not approved for clinical use by regulatory agencies including the FDA or EMA. All research involving these compounds should be conducted under appropriate institutional oversight, including IACUC (Institutional Animal Care and Use Committee) approval for animal studies and IRB (Institutional Review Board) oversight for any human research contexts. Researchers should familiarize themselves with applicable regulations in their jurisdiction.
Disclaimer
For research purposes only. Not for human consumption.
The information provided in this article is intended exclusively for educational and scientific research purposes. CJC-1295 with DAC and CJC-1295 without DAC are not approved pharmaceutical products and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. All research involving these compounds should be conducted by qualified researchers in appropriate laboratory settings with applicable institutional oversight and regulatory compliance. The studies and findings cited herein are presented for scientific informational purposes only and do not constitute medical advice or endorsement of any particular research protocol. Researchers are responsible for ensuring full compliance with all applicable local, national, and international regulations governing the acquisition, storage, and use of research compounds.